Pamela Klein
InvestorFounder and Principal, PMK BioResearch at Ysios Capital
San Francisco, California, United States
About
Dr. Pamela M. Klein is founder and principal of PMK BioResearch, providing advisory and strategic consulting to the biotechnology industry, and serves as consulting Chief Medical Officer of Olema Oncology. She previously held Chief Medical Officer roles at several biotech companies, including Intellikine (acquired by Takeda), and worked at Genentech from 2001 to 2008, ending as Vice President of Development where she oversaw development of drugs such as trastuzumab, rituximab, pertuzumab and erlotinib. She earlier co-founded and served as research director for the National Cancer Institute–Navy Breast Care Center, holds a biology degree from California State University Northridge and a medical degree from Loyola University Chicago's Stritch School of Medicine, and trained in internal medicine and medical oncology.
Invests in
Biotech
Experience
- argenxIndependent Director; Board Of Directorscurrent2016 — presentThe Netherlands
- Frontier MedicinesIndependent Director; Board of Directorscurrent2023 — presentSouth San Francisco, California, United States
- ONA TherapeuticsIndependent Director, Board of Directorscurrent2023 — presentBarcelona, Catalonia, Spain
- Ysios CapitalVenture Partnercurrent2023 — presentBarcelona, Catalonia, Spain
- ShasqiBoard Director, Independentcurrent2023 — present
- PMK BioResearchOncologist - Independent Biotech/Pharma Consultant/Drug Development Strategycurrent2008 — present
- Patrys LimitedIndependent Director; Board Of Directors2019 — 2025Australia
- I-Mab BiopharmaInterim Chairperson, Board of Directors2024
- I-Mab BiopharmaIndependent Director; Board of Directors2020 — 2024United States; China
- F-star Therapeutics, Inc.Member, Board of Directors2020 — 2023United Kingdom
- Sardona TherapeuticsIndependent Director; Board of Directors2023San Francisco Bay Area
- Olema OncologyChief Medical Officer2019 — 2022San Francisco
- Spring Bank Pharmaceuticals, Inc.Member, Board of Directors2019 — 2020Massachusetts, United States
- Intellikine IncChief Medical Officer2008 — 2011
- GenentechVice President, Clinical Development, Oncology2001 — 2007
- National Cancer InstituteResearch Director, NCI-Navy Breast Center1995 — 2001
Skills & more
Biotechnology64Drug Development56Oncology81DiagnosticsClinical Research32Drug Discovery15Clinical Trials20Clinical Development50Cancer17FDA2Medicine5Hardware Diagnostics3
+12 more
BiomarkersLifesciencesMolecular BiologyPharmaceutical IndustryImmunologyInfectious DiseasesTranslational ResearchHematologyMedical AffairsINDPharmacologyAssay DevelopmentFrom Pamela's professional profile.
Investments
Board seats
ArgenxF-Star TherapeuticsI-Mab BiopharmaJiya Acquisition CorporationPatrys
Per the firm's website.
Colleagues at Ysios Capital
Almudena Méndez
Associate at Ysios Capital
Antoni Ribas
Venture Partner at Ysios Capital
Arturo Urrios
Partner at Ysios Capital
Carlos Garcia-Echeverria
Venture Partner at Ysios Capital
Carlos Paya
Venture Partner at Ysios Capital
Catalina Cuchy
Executive Assistant at Ysios Capital
Cristina Garmendia
General Partner at Ysios Capital
David L. Lacey
Venture Partner at Ysios Capital
Frequently asked questions
- Who is Pamela Klein?
- Dr. Pamela M. Klein is founder and principal of PMK BioResearch, providing advisory and strategic consulting to the biotechnology industry, and serves as consulting Chief Medical Officer of Olema Oncology. She previously held Chief Medical Officer roles at several biotech companies, including Intellikine (acquired by Takeda), and worked at Genentech from 2001 to 2008, ending as Vice President of Development where she oversaw development of drugs such as trastuzumab, rituximab, pertuzumab and erlotinib. She earlier co-founded and served as research director for the National Cancer Institute–Navy Breast Care Center, holds a biology degree from California State University Northridge and a medical degree from Loyola University Chicago's Stritch School of Medicine, and trained in internal medicine and medical oncology.
- Where does Pamela Klein work?
- Pamela Klein is Founder and Principal, PMK BioResearch at Ysios Capital.
- What does Pamela Klein invest in?
- Pamela Klein invests in Biotech.
- What boards does Pamela Klein sit on?
- Pamela Klein holds tracked board seats at Argenx, F-Star Therapeutics, I-Mab Biopharma, Jiya Acquisition Corporation, Patrys.
- Where did Pamela Klein go to school?
- Pamela Klein studied at Loyola University Chicago Stritch School of Medicine (M.D., Oncology); California State University, Northridge (Bachelor's degree, Biology).
Same school
Also attended Loyola University Chicago Stritch School of Medicine2
.png)
Also attended California State University, Northridge34
Cynthia Jean KemberHead of Media, Content, Platforms and Partnerships at Type One VenturesSerafina MaulupeExecutive Assistant at Navitas CapitalBrian KadotaDirector of Venture Operations at Wavemaker Three-Sixty HealthJeff SchmidtHead of Commercialization at Energize VenturesMarcel LopezSupply Chain and Operations Partner at True Beauty VenturesJenna BryantCo-Founder, CEO and General Partner at Embedded Ventures
+ 28 more
Shared employers
Also worked at Frontier Medicines2
Also worked at ONA Therapeutics8
Clara CampàsCo-founder and managing partner at Asabys PartnersGuillem MasferrerPartner at Asabys PartnersMontse VendrellPartner at Asabys PartnersJoël Jean-MairetManaging Partner at Ysios CapitalJonathan DupontAssociate at Mérieux Equity PartnersThomas MackiolInvestment Manager at CFH Management GmbH
+ 2 more
Also worked at Patrys Limited1
Also worked at F-star Therapeutics, Inc.7
Charles GrummittInvestor at MedicxiNessan BerminghamInvestor at Khosla VenturesJim GolubieskiPresident at Foundation Venture Capital Group, LLCJeffrey MoorePresident at MC Healthcare VenturesDeborah HarlandChair, LifeArc Ventures Investment Committee at LifeArc VenturesOliver SimsBio at Octopus Ventures
+ 1 more